UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 136

Sortiert nach

US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-01, Vol.9 (1), p.132-150.e3

2021

Volltextzugriff (PDF)

Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

Annals of allergy, asthma, & immunology, 2011-12, Vol.107 (6), p.529-537.e2

2011

Volltextzugriff (PDF)

An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema

Orphanet journal of rare diseases, 2024-06, Vol.19 (1), p.241-10, Article 241

2024

Volltextzugriff (PDF)

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema

Annals of allergy, asthma, & immunology, 2010-06, Vol.104 (6), p.523-529

2010

Volltextzugriff (PDF)

The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression

Allergy and asthma proceedings, 2010-09, Vol.31 (5), p.407

2010

Volltextzugriff (PDF)

US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2013-09, Vol.1 (5), p.458-467

2013

Volltextzugriff (PDF)

Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema

Immunology and allergy clinics of North America, 2017-08, Vol.37 (3), p.617-628

Lumry, William R., MD

2017

Volltextzugriff (PDF)

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-06, Vol.9 (6), p.2305-2314.e4

2021

Volltextzugriff (PDF)

A Consensus Parameter for the Evaluation and Management of Angioedema in the Emergency Department

Academic emergency medicine, 2014-04, Vol.21 (4), p.469-484

2014

Volltextzugriff (PDF)

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Orphanet journal of rare diseases, 2021-02, Vol.16 (1), p.86-86, Article 86

2021

Volltextzugriff (PDF)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Frontiers in immunology, 2021-07, Vol.12, p.707463-707463

2021

Volltextzugriff (PDF)

Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-11, Vol.7 (8), p.2938-2940

2019

Volltextzugriff (PDF)

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

International archives of allergy and immunology, 2015-01, Vol.168 (1), p.44-55

2015

Volltextzugriff (PDF)

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Orphanet journal of rare diseases, 2021-07, Vol.16 (1), p.1-329, Article 329

2021

Volltextzugriff (PDF)

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

Clinical and translational allergy, 2023-09, Vol.13 (9), p.e12288-e12288

2023

Volltextzugriff (PDF)

Current and emerging therapies to prevent hereditary angioedema attacks

The American journal of managed care, 2018-08, Vol.24 (14 Suppl), p.S299-S307

Lumry, William R

2018

Volltextzugriff (PDF)

Switch from Intravenous C1-Inhibitor C1-INH(IV) to Subcutaneous C1-Inhibitor [C1 INH(SC)] for Routine Prevention of Hereditary Angioedema (HAE) Attacks: Subgroup Findings from the Compact Trial

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB230-AB230

2017

Volltextzugriff (PDF)

Characterization of Anaphylaxis After Ecallantide Treatment of Hereditary Angioedema Attacks

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2015-03, Vol.3 (2), p.206-212.e4

2015

Volltextzugriff (PDF)

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2018-11, Vol.320 (20), p.2108

2018

Volltextzugriff (PDF)

Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management

Clinical therapeutics, 2021-12, Vol.43 (12), p.2154-2166.e1

2021

Volltextzugriff (PDF)

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

The New England journal of medicine, 2017-03, Vol.376 (12), p.1131-1140

2017

Volltextzugriff (PDF)

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2022-03, Vol.399 (10328), p.945-955

2022

Volltextzugriff (PDF)

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Journal of allergy and clinical immunology, 2021-07, Vol.148 (1), p.164-172.e9

2021

Volltextzugriff (PDF)

Comparison of Chromogenic and ELISA Functional C1 Inhibitor Tests in Diagnosing Hereditary Angioedema

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2015-03, Vol.3 (2), p.200-205

2015

Volltextzugriff (PDF)

Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema

Annals of allergy, asthma, & immunology, 2023-07, Vol.131 (1), p.101-108.e3

2023

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(116)

Publikationsform

Artikel
(136)

Sprache

Englisch
(136)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(93)
Science & Technology
(93)
Humans
(85)
Allergy
(65)
Female
(55)
Immunology
(54)
Adult
(52)
Male
(49)
Angioedema
(48)
Middle Aged
(40)
Hereditary Angioedema
(39)
Angioedemas, Hereditary - Drug Therapy
(35)
Treatment Outcome
(35)
Edema
(34)
Quality Of Life
(34)
Aged
(32)
Double-Blind Method
(31)
Adolescent
(30)
Allergy And Immunology
(25)
Patients
(24)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema

Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema

The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression

US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency

Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

A Consensus Parameter for the Evaluation and Management of Angioedema in the Emergency Department

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

Current and emerging therapies to prevent hereditary angioedema attacks

Switch from Intravenous C1-Inhibitor C1-INH(IV) to Subcutaneous C1-Inhibitor [C1 INH(SC)] for Routine Prevention of Hereditary Angioedema (HAE) Attacks: Subgroup Findings from the Compact Trial

Characterization of Anaphylaxis After Ecallantide Treatment of Hereditary Angioedema Attacks

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial

Comparison of Chromogenic and ELISA Functional C1 Inhibitor Tests in Diagnosing Hereditary Angioedema

Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema

Suchergebnisse filtern